Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

10,006

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

10,006 results for “random”

Learn how ShareScore rates datasets ↗
zenodo12/100

Dataset related to article "Endoscopic ultrasound-guided fine-needle biopsy with or without macroscopic on-site evaluation: a randomized controlled noninferiority trial "

<p>This record contains raw data related to article &ldquo;Endoscopic ultrasound-guided fine-needle biopsy with or without macroscopic on-site evaluation: a randomized controlled noninferiority trial&quot;</p> <p>Abstract</p> <p>BACKGROUND : The advantage of using the macroscopic on-site evaluation (MOSE) technique during endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) performed with 22G Franseen needles has not been investigated. We aimed to compare EUS-FNB with MOSE vs. EUS-FNB performed with three needle passes. METHODS : This randomized trial involved 10 Italian referral centers. Consecutive patients referred for EUS-FNB of pancreatic or nonpancreatic solid lesions were included in the study and randomized to the two groups. MOSE was performed by gross visualization of the collected material by the endoscopists and considered adequate when a white/yellowish aggregate core longer than 10 mm was retrieved. The primary outcome was diagnostic accuracy. Secondary outcomes were specimen adequacy, number of needle passes, and safety. RESULTS : 370 patients with 234 pancreatic lesions (63.2 %) and 136 nonpancreatic lesions (36.8 %) were randomized (190 EUS-FNB with MOSE and 180 with standard EUS-FNB). No statistically significant differences were found between EUS-FNB with MOSE and conventional EUS-FNB in terms of diagnostic accuracy (90.0 % [95 %CI 84.8 %-93.9 %] vs. 87.8 % [95 %CI 82.1 %-92.2 %]; <em>P</em> = 0.49), sample adequacy (93.1 % [95 %CI 88.6 %-96.3 %] vs. 95.5 % [95 %CI 91.4 %-98 %]; <em>P</em> = 0.31), and rate of adverse events (2.6 % vs. 1.1 %; <em>P</em> = 0.28). The median number of passes was significantly lower in the EUS-FNB with MOSE group (1 vs. 3; <em>P</em> &lt; 0.001). CONCLUSIONS : The accuracy of EUS-FNB with MOSE is noninferior to that of EUS-FNB with three needle passes. MOSE reliably assesses sample adequacy and reduces the number of needle passes required to obtain the diagnosis with a 22G Franseen needle.</p>

restrictedJan 2023View details →
zenodo12/100

dataset Is positive communication sufficient to modulate procedural pain and anxiety in the emergency room? A randomized controlled trial.

<p>Our&nbsp; study aimed to modulate contents and delivery vector of a message regarding peripheral intravenous catheter (PIC) placement in the emergency room (ER), to test if therapeutic communication could enhance patients&#39; comfort during minor medical procedures. This study was a 2+2 randomized controlled trial. A positive versus standard message was delivered through audio tape (double blind) in the first phase (N= 131) and through the nurse in charge of the catheter placement (single blind) in the second phase (N= 120).</p>

restrictedJan 2023View details →
zenodo12/100

Dataset related to the publication by Pan et al.: A randomized clinical trial of two-staged tourniquet strategy for total knee arthroplasty

<p>Dataset related to the publication by Pan et al. 2023.</p> <p>A randomized clinical trial of two-staged tourniquet strategy for total knee arthroplasty</p>

restrictedMay 2023View details →
zenodo12/100

Data related to article EFFICACY OF MINDFULNESS ADDED TO TREATMENT AS USUAL IN PATIENTS WITH CHRONIC MIGRAINE AND MEDICATION OVERUSE HEADACHE: A PHASE-III SINGLE-BLIND RANDOMIZED-CONTROLLED TRIAL (THE MIND-CM STUDY) - submitted

<p>DATA ON PATIENTS INCLUDED IN THE MIND-CM STUDY. TWO ARMS (TAU AND TAU+MIND), AND FOUR EVALUATIONS: BASELINE, 3-MONTHS, 6-MONTHS AND 12-MONTS FOLLOW-UP.</p>

restrictedJul 2023View details →
zenodo12/100

Comparing Effects of Ultra Low Dose (Ethinyl Estradiol 20µg or 15µg) with Low Dose (Ethinyl Estradiol 30µg) Hormonal Pills on Lipid Discordance in Non-Obese PCOS Women: A Randomized Control Trial

<p>Ultra-low dose hormonal pills have become the favoured treatment option over low dose pills in PCOS. Existing literature shows marked heterogeneity in metabolic effects of pills with different compositions. This might have been due to improper choice of outcome variable for comparison. Total cholesterol - high density lipoprotein ratio (TC/HDL) discordance with Low Density Lipoprotein cholesterol (LDL-C) was a better marker of future risk of atherosclerotic cardio-vascular disease and stable to variations. Present study was a randomised controlled trial conducted to compare prevalence of TC/HDL and LDL discordance among non-obese PCOS women treated with hormonal pills of different compositions. Role of baseline participant features and pill composition on discordance after treatment was determined. Women were randomised into three arms, two arms receiving ultra-low dose pills (either Ethinyl Estradiol 20&micro;g with drosperinone 3mg or Ethinyl Estradiol 15&micro;g with gestodene 60&micro;g) and one arm receiving low dose pill (Ethinyl Estradiol 30&micro;g with desogestrel 150 &micro;g). Discordance was observed in more than 1/4<sup>th</sup> participants prior to intervention. After one year of treatment less than 1/5<sup>th</sup> of participants were discordant. Ultra-low dose pill users had lower discordance, LDL and TC compared to low dose pill users after one year of treatment. Random Forest a non-linear classifier showed the highest accuracy in predicting discordance. Baseline Parameters having maximal impact on occurrence of discordance were triglyceride (TG), HOMA-IR, BMI and HDL.Ultra-low dose hormonal pills have become the favoured treatment option over low dose pills in PCOS. Existing literature shows marked heterogeneity in metabolic effects of pills with different compositions. This might have been due to improper choice of outcome variable for comparison. Total cholesterol - high density lipoprotein ratio (TC/HDL) discordance with Low Density Lipoprotein cholesterol (LDL-C) was a better marker of future risk of atherosclerotic cardio-vascular disease and stable to variations. Present study was a randomised controlled trial conducted to compare prevalence of TC/HDL and LDL discordance among non-obese PCOS women treated with hormonal pills of different compositions. Role of baseline participant features and pill composition on discordance after treatment was determined. Women were randomised into three arms, two arms receiving ultra-low dose pills (either Ethinyl Estradiol 20&micro;g with drosperinone 3mg or Ethinyl Estradiol 15&micro;g with gestodene 60&micro;g) and one arm receiving low dose pill (Ethinyl Estradiol 30&micro;g with desogestrel 150 &micro;g). Discordance was observed in more than 1/4<sup>th</sup> participants prior to intervention. After one year of treatment less than 1/5<sup>th</sup> of participants were discordant. Ultra-low dose pill users had lower discordance, LDL and TC compared to low dose pill users after one year of treatment. Random Forest a non-linear classifier showed the highest accuracy in predicting discordance. Baseline Parameters having maximal impact on occurrence of discordance were triglyceride (TG), HOMA-IR, BMI and HDL.</p>

restrictedJul 2023View details →
zenodo12/100

Opendata for the manuscript"Study on permeability for random packed porous media using lattice Boltzmann method"

Open the record for dataset details and reuse information.

restrictedcc-by-4.0Oct 2023View details →
zenodo12/100

Dataset related to article "Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial"

<p>This record contains raw data related to article "Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial"</p><p>Abstract</p><p><strong>Aims: </strong>We report the mature toxicity data of a phase II non-randomized trial on the use of SBRT for lung and liver oligometastases.</p><p><strong>Methods: </strong>Oligometastatic patients from breast cancer were treated with SBRT for up to five lung and/or liver lesions. Inclusion criteria were: age &gt; 18 years, ECOG 0-2, diagnosis of breast cancer, less than five lung/liver lesions (with a maximum diameter &lt;5 cm), metastatic disease confined to the lungs and liver or extrapulmonary or extrahepatic disease stable or responding to systemic therapy. Various dose-fractionation schedules were used. Then, a 4D-CT scan and FDG-CTPET were acquired for simulation and fused for target definition.</p><p><strong>Results: </strong>From 2015 to 2021, 64 patients and a total of 90 lesions were irradiated. Treatment was well tolerated, with no G 3-4 toxicities. No grade ≥3 toxicities were registered and the coprimary endpoint of the study was met. Median follow-up was 19.4 months (range 2.6-73.1).</p><p><strong>Conclusions: </strong>The co-primary endpoint of this phase II trial was met, showing excellent tolerability of SBRT for lung and liver oligometastatic in breast cancer patients. Until efficacy data will mature with longer follow-up, SBRT should be regarded as an opportunity for oligometastatic breast cancer patients.</p>

restrictedOct 2023View details →
zenodo12/100

Dataset related to article "Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform"

<p>This record contains raw data related to article "Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform"</p><p>Abstract</p><p>Background: Comparative prospective data regarding different radiosurgery (SRS) modalities for treating brain metastases (BMs) from solid tumors are not available. To investigate with a single institute phase III randomized trial whether SRS executed with linac (Arm-B) is superior to a dedicated multi-source gamma-ray stereotactic platform (Arm-A).</p><p>Methods: Adults patients with 1-4 BMs from solid tumors up to 30 mm in maximum diameter were randomly assigned to arms A and B. The primary endpoint was cumulative incidence of symptomatic (grade 2-3) radionecrosis (CIRN). Secondary endpoints were local progression cumulative incidence (CILP), distant brain failure, disease-free survival (DFS), and overall survival (OS).</p><p>Results: A total of 251 patients were randomly assigned to Arm-A (121) or Arm-B (130). The 1-year RN cumulative incidence was 6.7% in whole cohort, 3.8% (95% CI 1.9-7.4%) in Arm-B, and 9.3% (95% CI 6.2-13.8%) in the Arm-A (p = 0.43). CIRN was influenced by target volume irradiated only for the Arm-A (p &lt;&lt; 0.001; HR 1.36 [95% CI 1.25-1.48]). Symptomatic RN occurred in 56 cases at a median time of 10.3 months (range 1.15-54.8 months), 27 in the Arm-B at a median time of 15.9 months (range 4.9-54.8 months), and 29 in the Arm-A at a median time of 6.9 months (1.2-32.3 months), without statistically significant differences between the two arms. No statistically significant differences were recorded between the two arms in CILP, BDF, DFS or OS. The mean beam-on time to deliver SRS was 49.0 ± 36.2 min in Arm-A, and 3.1 ± 1.6 min in Arm-B.</p><p>Conclusions: Given the technical differences between the treatment platforms investigated in this single-institution study, linac-based SRS (Arm-B) did not lead to significantly lower grade 2-3 RN rates versus the multi-source gamma-ray system (Arm-A) in a population of patients with limited brain metastases of small volume. No significant difference in local control was observed between both arms. For Arm-B, the treatment delivery time was significantly lower than for Arm-A.</p><p>&nbsp;</p><p>Trial registration: ClinicalTrials.gov Identifier NCT02355613.</p><p>&nbsp;</p>

restrictedOct 2023View details →
ClinicalTrials.gov12/100

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine

ClinicalTrials.gov study NCT00000835. IPD Sharing: Not stated. Countries: 0. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
geo12/100

eqtl analysis (random pair design)-Establishing the network of seed gene expression and analysis of its biodiversity

GEO Series GSE16393. Arabidopsis thaliana. 160 samples. Type: Expression profiling by array.

openGEO-OpenJun 2009View details →
geo12/100

Implementing whole genome array for clinical use in academic centers: A randomized trial comparing neoadjuvant standard chemotherapy to genomic-driven chemotherapy in operable breast cancer (REMAGUS04

GEO Series GSE63471. Homo sapiens. 142 samples. Type: Expression profiling by array.

openGEO-OpenJul 2016View details →
zenodo8/100

Dataset for "A random-walk benchmark for single-electron circuits"

<p>Data used to generate the figures in the publication &quot;A random-walk benchmark for single-electron circuits&quot;.</p>

restrictedNov 2020View details →
zenodo8/100

Effects of β2-receptor stimulation by indacaterol in chronic heart failure treated with selective or non-selective β-blockers: a randomized trial

<p>Raw data of the paper:&nbsp;<strong>Effects of &beta;<sub>2</sub>-receptor stimulation by indacaterol in chronic heart failure treated with selective or non-selective &beta;-blockers: a randomized trial</strong></p>

restrictedDec 2020View details →
zenodo8/100

More random stuff

<p>Even More random stuff explaining random stuff.</p>

restrictedDec 2016View details →
zenodo8/100

Dataset related to article "Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment "

<p>This record contains raw data related to article "Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment"</p><p>Abstract</p><p><strong>Background: </strong>The initial results of the SINODAR-ONE randomized clinical trial reported that patients with T1-2 breast cancer and one to two macrometastatic sentinel lymph nodes treated with breast-conserving surgery, sentinel lymph node biopsy only, and adjuvant therapy did not present worse 3-year survival, regional recurrence, or distant recurrence rates compared with those treated with axillary lymph node dissection. To extend the recommendation of axillary lymph node dissection omission even in patients treated with mastectomy, a sub-analysis of the SINODAR-ONE trial is presented here.</p><p><strong>Methods: </strong>Patients with T1-2 breast cancer and no more than two metastatic sentinel lymph nodes undergoing mastectomy were analysed. After sentinel lymph node biopsy, patients were randomly assigned to receive either axillary lymph node dissection followed by adjuvant treatment (standard arm) or adjuvant treatment alone (experimental arm). The primary endpoint was overall survival. The secondary endpoint was recurrence-free survival.</p><p><strong>Results: </strong>A total of 218 patients were treated with mastectomy; 111 were randomly assigned to the axillary lymph node dissection group and 107 to the sentinel lymph node biopsy-only group. At a median follow-up of 33.0 months, there were three deaths (two deaths in the axillary lymph node dissection group and one death in the sentinel lymph node biopsy-only group). There were five recurrences in each treatment arm. No axillary lymph node recurrence was observed. The 5-year overall survival rates were 97.8 and 98.7 per cent in the axillary lymph node dissection treatment arm and the sentinel lymph node biopsy-only treatment arm, respectively (P = 0.597). The 5-year recurrence-free survival rates were 95.7 and 94.1 per cent in the axillary lymph node dissection treatment arm and the sentinel lymph node biopsy treatment arm, respectively (P = 0.821).</p><p><strong>Conclusion: </strong>In patients with T1-2 breast cancer and one to two macrometastatic sentinel lymph nodes treated with mastectomy, the overall survival and recurrence-free survival rates of patients treated with sentinel lymph node biopsy only were not inferior to those treated with axillary lymph node dissection. To strengthen the conclusion of the trial, the enrolment of patients treated with mastectomy was reopened as a single-arm experimental study.</p><p>&nbsp;</p>

restrictedNov 2023View details →
zenodo8/100

Management of potentially inappropriate drug prescriptions among Lebanese patients in primary care settings -the MGPIDP-L project: Description of an interventional prospective non-randomized study

<p>The aim of our study was to evaluate &nbsp;potentially inappropriate prescriptions among Lebanese geriatric population in primary care settings using the latest versions of Beers criteria, Laroche, European Union&nbsp; 7 (EU7), STOPP START, and STOPP Frail.&nbsp;Our secondary objectives were to assess disease related factors ,drug/therapy related factors, the proposed pharmaceutical interventions, and the satisfaction of the patients after performing the medication review.</p>

restrictedFeb 2022View details →
zenodo8/100

Collection of randomized trials to assess efficacy of treatments against STH

<p>Seven randomized trials conducted in C&ocirc;te d&rsquo;Ivoire, Lao PDR, and Tanzania, which assess&nbsp;the efficacy and safety of different treatments against STH infection.</p>

restrictedOct 2022View details →
zenodo8/100

A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system

<p>This dataset reports data from a&nbsp;randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system.</p>

restrictedJan 2023View details →
zenodo8/100

Data from; Concentration-Dependent Impact of Green Tea Catechin Gargling on Acute Upper Respiratory Tract Infections: An Exploratory Randomized Controlled Trial

<p>We conducted an open-label randomized study (UMIN000045060). The target population consisted of 209 students from the University of Shizuoka and Meiji University, who were randomly assigned to high-catechin (70 participants, approximate catechin concentration: 76.4 mg/dL), low-catechin (69 participants, approximate catechin concentration: 30.8 mg/dL), and a control water gargling (70 participants, catechin concentration: 0 mg/dL) groups. All participants gargled water or GT thrice daily for 12 weeks between December 2021 and February 2022. The symptoms experienced by participants who developed URTI during the study period were recorded on a survey form. The primary endpoint of URTI occurred in 6 (9.1%), 7 (10.8%), and 11 (15.7%) participants in the high-catechin, low-catechin, and water groups, respectively (Fisher&#39;s exact test for the overall group: <em>p</em>=0.482). Cox proportional hazards analysis, using background factors and prevention status as covariates, revealed a hazard ratio of 0.57 (95% CI: 0.21&ndash;1.55, <em>p</em>=0.261) for the high-catechin vs. water group and 0.54 (95% CI: 0.20&ndash;1.50, <em>p</em>=0.341) for the low-catechin vs. water group.</p>

restrictedMay 2023View details →
zenodo4/100

test collection with random binary data

<p>This is a collection with three files containing random binary data.</p>

restrictedSep 2014View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.